av人人,99热这里只有精品99,国产一卡2卡3卡4卡网站贰佰

Rongchang Biopharma H1 2025 Financial Report Rongchang Biopharma Rongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.
Dizal Pharma H1 2025 Financial Report Dizal Pharma Dizal Pharma reports its strongest half-year results in history, achieving first commercialization profit, accelerating R&D, and advancing global expansion with FDA-approved therapies.
Sino Biopharmaceutical H1 2025 Financial Report Sino Biopharmaceutical Sino Biopharmaceutical reported RMB 17.57B revenue in 1H 2025, up 10.7%. Innovative products grew 27.2% to RMB 7.80B. R&D investment hit RMB 3.19B, with multiple new drug approvals and acquisitions.
WuXi XDC H1 2025 Financial Report WuXi XDC WuXi XDC's 2025 half-year report: revenue RMB 2.701B (+62.2%), net profit RMB 746M (+52.7%), 563 global customers, 225 iCMC projects, backlog USD 1.329B, major capacity expansion in Wuxi and Singapore.
CARsgen Therapeutics H1 2025 Financial Report CARsgen CARsgen Therapeutics 2025 H1 results: revenue RMB 509.61M (+703.8% YoY), driven by BCMA CAR-T ZeKeze?. Pipeline updates include CT041 NDA acceptance, solid tumor CAR-T breakthroughs, and multiple allogeneic CAR-T developments.
Wanhua Chemical H1 2025 Financial Report Wanhua Chemical Group Wanhua Chemical posted H1 2025 revenue of RMB 90.9B, down 6.35%, with net profit down 25.1%. Business performance varied across polyurethane, petrochemical, and new materials segments.
Gilead Q2 2025 Financial Report Financial statements Gilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.
Sutro Biopharma H1 2025 Financial Report Financial statements Sutro Biopharma rebounds after major restructuring, posting 110% H1 2025 revenue growth. With strong cash reserves, strategic ADC pipeline advances, and key partnerships, it targets critical milestones through 2027.
BeOne(BeiGene) Q2 2025 Interim Financial Report BeiGene BeiGene reported a net profit of 450 million yuan for H1 2025, marking its first interim profit since A-share listing. Strong product sales and revised revenue and margin forecasts signal sustainable growth.
2025 H1 Global Pharma Earnings Panorama Financial statements A comprehensive analysis of global pharma earnings in H1 2025, highlighting innovation-driven growth, key players like Novartis, Novo Nordisk, AstraZeneca, Sanofi, and BeiGene, and trends shaping the industry’s future.

< Pre 1 234 5 6 7 8...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a